Physician profile
Kate M Smith
NPI 1063260131
$2,377.03
in general payments reported to CMS, 2019-2025
31 companies · $2,154 in 2025
The $2,154 reported for 2025 was more than what 94% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $223 · 2025: $2,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,377.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $400.09 | 2025 | |
| Lilly USA, LLC | $237.62 | 2025 | Kisunla |
| Biogen, INC. | $218.99 | 2025 | Vumerity, Tysabri, Skyclarys |
| Eisai INC. | $211.42 | 2025 | |
| Amneal Pharmaceuticals LLC | $184.79 | 2025 | Ongentys, Crexont |
| Organogenesis INC. | $157.70 | 2024 | |
| Pfizer INC. | $146.03 | 2025 | |
| Lundbeck LLC | $105.62 | 2025 | Vyepti |
| Argenx US, INC. | $71.00 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Ucb, INC. | $68.31 | 2025 | Fintepla, Briviact, Rystiggo |
| Genentech USA, INC. | $62.15 | 2025 | Ocrevus Zunovo |
| Alexion Pharmaceuticals, INC. | $53.90 | 2025 | Ultomiris |
| Celgene Corporation | $50.37 | 2025 | Zeposia |
| Boston Scientific Corporation | $50.27 | 2025 | General - Dbs |
| Vanda Pharmaceuticals INC. | $34.51 | 2025 | Ponvory |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $33.72 | 2025 | Sunosi |
| Inspire Medical Systems, INC. | $32.11 | 2024 | Inspire |
| Teva Pharmaceuticals USA, INC. | $31.95 | 2025 | Austedo Xr |
| Janssen Biotech, INC. | $26.42 | 2025 | |
| C2n Diagnostics, LLC | $22.04 | 2025 | Precivityad2 |
| Jazz Pharmaceuticals INC. | $19.96 | 2025 | |
| Harmony Biosciences LLC | $19.72 | 2025 | |
| Novo Nordisk INC | $18.58 | 2024 | Ozempic |
| Amgen INC. | $17.71 | 2025 | Uplizna |
| Neurocrine Biosciences, INC. | $17.01 | 2025 | |
| Acadia Pharmaceuticals INC | $16.78 | 2025 | Nuplazid |
| Merz Pharmaceuticals, LLC | $16.11 | 2025 | Xeomin |
| Emd Serono, INC. | $15.33 | 2025 | Mavenclad |
| Octapharma USA, INC. | $14.78 | 2025 | Panzyga |
| Astrazeneca Pharmaceuticals LP | $14.50 | 2024 | |
| Aucta Pharmaceuticals, INC. | $7.54 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kate Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.